MX377115B - Gangliosidos para estandarizacion y aumento de la sensibilidad de las celulas a las neurotoxinas botulinicas en sistemas de prueba in vitro. - Google Patents
Gangliosidos para estandarizacion y aumento de la sensibilidad de las celulas a las neurotoxinas botulinicas en sistemas de prueba in vitro.Info
- Publication number
- MX377115B MX377115B MX2016010144A MX2016010144A MX377115B MX 377115 B MX377115 B MX 377115B MX 2016010144 A MX2016010144 A MX 2016010144A MX 2016010144 A MX2016010144 A MX 2016010144A MX 377115 B MX377115 B MX 377115B
- Authority
- MX
- Mexico
- Prior art keywords
- pluripotent stem
- induced pluripotent
- neurons
- derived
- neurotoxin polypeptide
- Prior art date
Links
- 230000035945 sensitivity Effects 0.000 title abstract 7
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
- 150000002270 gangliosides Chemical class 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 15
- 210000002569 neuron Anatomy 0.000 abstract 14
- 101710138657 Neurotoxin Proteins 0.000 abstract 12
- 239000002581 neurotoxin Substances 0.000 abstract 12
- 231100000618 neurotoxin Toxicity 0.000 abstract 12
- 229920001184 polypeptide Polymers 0.000 abstract 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 12
- 238000012258 culturing Methods 0.000 abstract 5
- 230000004071 biological effect Effects 0.000 abstract 4
- 239000006143 cell culture medium Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un método para la estandarización de la sensibilidad de las neuronas derivadas de las células madre pluripotentes inducidas (iPS) con respecto a un polipéptido de una neurotoxina, que comprende las etapas de: a) cultivar diferentes lotes de neuronas derivadas de las células madre pluripotentes inducidas en un medio de cultivo de las células que comprende GT1b durante al menos 3 horas; b) poner en contacto los diferentes lotes de las neuronas derivadas de las células madre pluripotentes inducidas de la etapa a) con un polipéptido de neurotoxina; c) cultivar los diferentes lotes de neuronas derivadas de las células madre pluripotentes inducidas de la etapa b) durante al menos 24 horas en la presencia de GT1b en condiciones que permitan al polipéptido de neurotoxina ejercer su actividad biológica estandarizando de este modo la sensibilidad de las neuronas derivadas de las células madre pluripotentes inducidas con respecto a un polipéptido de una neurotoxina. La invención se refiere además a un método para la generación de neuronas derivadas de las células madre pluripotentes inducidas que tienen una sensibilidad estandarizada con respecto a un polipéptido de neurotoxina, que comprende las etapas de: a) proporcionar diferentes lotes de las neuronas derivadas de las células madre pluripotentes inducidas; b) cultivar los diferentes lotes de las neuronas derivadas de las células madre pluripotentes inducidas de la etapa a) en un medio de cultivo celular que comprende GT1b durante al menos 3 horas, estandarizando de este modo la sensibilidad de las neuronas derivadas de las células madre pluripotentes inducidas con respecto a un polipéptido de neurotoxina. Además, está abarcado por la presente invención un método para determinar la actividad biológica de un polipéptido de neurotoxina, que comprende las etapas de: a) cultivar las neuronas derivadas de las células madre pluripotentes inducidas en un medio de cultivo celular que comprende GT1b durante al menos 3 horas; b) poner en contacto las neuronas derivadas de las células madre pluripotentes inducidas de la etapa a) con un polipéptido de neurotoxina; c) cultivar las neuronas derivadas de las células madre pluripotentes inducidas de la etapa b) durante al menos 24 horas en la presencia de GT1b bajo condiciones que permitan al polipéptido de neurotoxina ejercer su actividad biológica; y d) determinar la actividad biológica del polipéptido de neurotoxina en las células. Finalmente, la invención se refiere al uso de GT1b para a) la estandarización de la sensibilidad de los diferentes lotes de las neuronas derivadas de las células madre pluripotentes inducidas con respecto a un polipéptido de neurotoxina; o b) la reducción de la variabilidad de la sensibilidad de los diferentes lotes de neuronas derivadas de las células madre pluripotentes inducidas con respecto a un polipéptido de neurotoxina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14155726 | 2014-02-19 | ||
| PCT/EP2015/053403 WO2015124618A1 (en) | 2014-02-19 | 2015-02-18 | Gangliosides for standardizing and increasing the sensitivity of cells to botulinum neurotoxins in in vitro test systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010144A MX2016010144A (es) | 2016-10-07 |
| MX377115B true MX377115B (es) | 2025-03-07 |
Family
ID=50115731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010144A MX377115B (es) | 2014-02-19 | 2015-02-18 | Gangliosidos para estandarizacion y aumento de la sensibilidad de las celulas a las neurotoxinas botulinicas en sistemas de prueba in vitro. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10921312B2 (es) |
| EP (1) | EP3108243B1 (es) |
| JP (1) | JP6549599B2 (es) |
| KR (1) | KR102282266B1 (es) |
| CN (1) | CN106133522B (es) |
| AU (1) | AU2015220915B2 (es) |
| BR (1) | BR112016019104A2 (es) |
| CA (1) | CA2940082C (es) |
| ES (1) | ES2812769T3 (es) |
| IL (1) | IL247162A0 (es) |
| MX (1) | MX377115B (es) |
| RU (1) | RU2694191C2 (es) |
| SG (1) | SG11201606810SA (es) |
| WO (1) | WO2015124618A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3014267T3 (pl) | 2013-06-28 | 2019-05-31 | Merz Pharma Gmbh & Co Kgaa | Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach |
| WO2019069378A1 (ja) | 2017-10-03 | 2019-04-11 | オリンパス株式会社 | 培養情報処理装置 |
| EP4014039A1 (en) * | 2019-08-13 | 2022-06-22 | Synaptic Research, LLC | Cells highly sensitive to clostridial neurotoxin |
| CN117887797B (zh) * | 2023-12-27 | 2024-09-20 | 中国食品药品检定研究院 | 一种梭状芽胞杆菌神经毒素效价检测方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| CA2753208C (en) | 2009-02-20 | 2018-08-21 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
| EP2401364B1 (en) | 2009-02-27 | 2015-04-22 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| DK2406371T3 (en) | 2009-03-13 | 2018-08-13 | Allergan Inc | USEFUL CELLS FOR IMMUNE BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY TEST |
| JP6185907B2 (ja) | 2011-03-30 | 2017-08-23 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 神経分化のための多能性幹細胞の予備刺激 |
-
2015
- 2015-02-18 MX MX2016010144A patent/MX377115B/es active IP Right Grant
- 2015-02-18 KR KR1020167024793A patent/KR102282266B1/ko active Active
- 2015-02-18 EP EP15705022.0A patent/EP3108243B1/en active Active
- 2015-02-18 BR BR112016019104A patent/BR112016019104A2/pt not_active Application Discontinuation
- 2015-02-18 SG SG11201606810SA patent/SG11201606810SA/en unknown
- 2015-02-18 RU RU2016131408A patent/RU2694191C2/ru active
- 2015-02-18 JP JP2016552628A patent/JP6549599B2/ja active Active
- 2015-02-18 CN CN201580009292.8A patent/CN106133522B/zh active Active
- 2015-02-18 AU AU2015220915A patent/AU2015220915B2/en active Active
- 2015-02-18 CA CA2940082A patent/CA2940082C/en active Active
- 2015-02-18 US US15/119,553 patent/US10921312B2/en active Active
- 2015-02-18 WO PCT/EP2015/053403 patent/WO2015124618A1/en not_active Ceased
- 2015-02-18 ES ES15705022T patent/ES2812769T3/es active Active
-
2016
- 2016-08-08 IL IL247162A patent/IL247162A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| HK1226481B (zh) | 2017-09-29 |
| MX2016010144A (es) | 2016-10-07 |
| EP3108243A1 (en) | 2016-12-28 |
| CA2940082A1 (en) | 2015-08-27 |
| RU2016131408A3 (es) | 2018-08-09 |
| JP2017506892A (ja) | 2017-03-16 |
| IL247162A0 (en) | 2016-09-29 |
| KR102282266B1 (ko) | 2021-07-27 |
| CA2940082C (en) | 2023-09-19 |
| US10921312B2 (en) | 2021-02-16 |
| CN106133522A (zh) | 2016-11-16 |
| AU2015220915A1 (en) | 2016-08-11 |
| AU2015220915B2 (en) | 2020-09-17 |
| SG11201606810SA (en) | 2016-09-29 |
| EP3108243B1 (en) | 2020-07-15 |
| KR20160120752A (ko) | 2016-10-18 |
| JP6549599B2 (ja) | 2019-07-24 |
| RU2016131408A (ru) | 2018-03-22 |
| CN106133522B (zh) | 2018-10-12 |
| RU2694191C2 (ru) | 2019-07-09 |
| WO2015124618A1 (en) | 2015-08-27 |
| ES2812769T3 (es) | 2021-03-18 |
| US20170059558A1 (en) | 2017-03-02 |
| BR112016019104A2 (pt) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000540A1 (es) | Método para aislar células madre mesenquimales a partir de membrana amniótica de cordón umbilical utilizando un medio de cultivo celular resumen de la invención. | |
| IL307568A (en) | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells | |
| MX377115B (es) | Gangliosidos para estandarizacion y aumento de la sensibilidad de las celulas a las neurotoxinas botulinicas en sistemas de prueba in vitro. | |
| MX2017013035A (es) | Sistema y metodo para la deteccion de alto rendimiento de celulas cancerigenas. | |
| EP2582795A4 (en) | METHOD FOR SELECTION OF HUMAN INDUCED PLURIPOTENTAL STEM CELLS | |
| TR201905632T4 (tr) | Bir tümörün tedavisinde kullanıma yönelik preeklamptik plasental mezenkimal kök hücre koşullu ortam. | |
| BR112019009746A2 (pt) | ensaio de células-tronco pluripotentes | |
| Rorteau et al. | Maintenance of chronological aging features in culture of normal human dermal fibroblasts from old donors | |
| BR112014026735A2 (pt) | aparelho de processamento de amostra biológica, e, método para operar um aparelho de processamento de amostra | |
| CR20190139A (es) | Preparación farmacéutica anti envejecimiento | |
| HK1245060A1 (zh) | 从生物样品的氧化还原电位测定生育力潜力 | |
| MX377925B (es) | Ensayo enzimatico con fluoroforos duplicados. | |
| BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| WO2015003160A3 (en) | Hepatocytes in co-culture and uses thereof | |
| BR112019003147A2 (pt) | uso de um marcador, métodos para identificar uma célula-tronco neural de mamífero e/ou uma célula progenitora neural de mamífero, para isolar uma célula-tronco neural de mamífero e/ou uma célula progenitora neural de mamífero, para determinar se um composto de teste modula uma diferenciação de célula-tronco neural de mamífero e/ou de célula progenitora neural de mamífero in vitro, para produzir uma população isolada de células de mamífero in vitro, para tratar doença ou dano e/ou prevenir e proteger contra dano no sistema nervoso em um indivíduo, para tratar um distúrbio mental ou comportamental em um indivíduo e para determinar as características de uma área danificada ou doente do snc em um paciente, cultura celular in vitro, cultura em suspensão, marcador para células-tronco neurais de mamífero e/ou para células progenitoras neurais de mamífero, e, composição. | |
| EA201891414A1 (ru) | Способ количественного определения пептидов для дифференцирования полноразмерного высокомолекулярного кининогена (вмк) и расщепленного вмк | |
| BR112018001256A2 (pt) | método de ensaio para avaliação de uma ou mais subclasses de células sanguíneas de interesse (bcoi), método para avaliar a quantidade de receptores de cd4 localizados nas superfícies de células cd4+ e opcionalmente, para avaliar a quantidade de receptores de cd8 localizados nas superfícies de células, dispositivo de ensaio de fluxo vertical para realizar um método, e, uso de um dispositivo. | |
| MX2017012758A (es) | Metodo y aparato para estimar la cantidad de microorganismos en una unidad taxonomica en una muestra. | |
| AR103745A1 (es) | Inmunoensayo homogéneo con compensación de la señal de fondo | |
| ES2509567T3 (es) | Identificación de variación genética en tejidos afectados | |
| AR105439A1 (es) | Procedimientos de purificación de un virus producido in vitro y ensayo de eliminación del virus | |
| Wang et al. | Glutathione peroxidase-1 is required for self-renewal of murine embryonic stem cells | |
| AR112851A1 (es) | Procedimiento para la obtención de una glicoproteína con un mayor porcentaje de glicanos afucosilados | |
| GB2550721A (en) | Optical measurement system | |
| AR094875A1 (es) | Formulaciones y procedimientos para la producción de proteína recombinante aumentada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |